Irreversible 4-aminopiperidine transglutaminase 2 inhibitors for Huntington's disease

ACS Medicinal Chemistry Letters

Volumn 3, Issue 9, 2012, Pages 731-735

  Prime, Michael E ^a   Brookfield, Frederick A ^a   Courtney, Stephen M ^a   Gaines, Simon ^a   Marston, Richard W ^a   Ichihara, Osamu ^a   Li, Marie ^a   Vaidya, Darshan ^a   Williams, Helen ^a   Pedret Dunn, Anna ^a   Reed, Laura ^a   Schaertl, Sabine ^b   Toledo Sherman, Leticia ^c   Beconi, Maria ^c   MacDonald, Douglas ^c   Muñoz Sanjuan, Ignacio ^c   Dominguez, Celia ^c   Wityak, John ^c  

^a EVOTEC UK LTD   (United Kingdom)

^b EVOTEC AG   (Germany)

^c CHDI MANAGEMENT CHDI FOUNDATION   (United States)

Author keywords

acrylamides; ADME; Celiac disease; computer aided drug design; plasma stability; SAR

Indexed keywords

4 AMINOPIPERIDINE DERIVATIVE; ACRYLAMIDE; ENZYME INHIBITOR; PIPERIDINE DERIVATIVE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; TISSUE TRANSGLUTAMINASE 2 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUNTINGTON CHOREA; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 84866354555     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml3001352     Document Type: Article

References (21)

1. Greenberg, C. S.; Birckbichler, R. H. Transglutaminases: Multifunctional cross-linking enzymes that stabilize tissues FASEB J. 1991, 5, 3071-3077
2. Im, M.-J.; Riek, P.; Graham, R. A novel guanine nucleotide-binding protein coupled to the α1-adrenergic receptor J. Biol. Chem. 1990, 265, 18952-18960
3. Lai, T.-S.; Slaughter, T.; Peoples, K.; Hettasch, J.; Greenburg, C. Regulation of human tissue transglutaminase function by magnesium-nucleotide complexes J. Biol. Chem. 1998, 273, 1776-1781
4. Hasegawa, G.; Suwa, M.; Ichikawa, Y.; Ohtsuka, T.; Kumagai, S.; Kikuchi, M.; Sato, Y.; Saito, Y. A novel function of tissue-type transglutaminase: protein disulfide isomerase Biochem. J. 2003, 373, 793-803
5. Pinkas, D.; Strop, P.; Brunger, A.; Khosla, C. Transglutaminase 2 undergoes a large conformational change upon activation PLOS Biol. 2007, 5, 2788-2796
6. Liu, S.; Cerione, R. A.; Clardy, J. Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 2743-2747
7. Stamnaes, J.; Pinkas, D. M.; Fleckenstein, B.; Khosla, C.; Sollid, L. M. Redox regulation of transglutaminase 2 activity J. Biol. Chem. 2010, 285, 25402-25409
8. Mastroberardino, P. G.; Farrace, M.; Viti, I.; Pavone, F.; Fimia, G.; Melino, G.; Kodolfo, C.; Piacentini, M. Tissue transglutaminase contributes to the formation of disulphide bridges in proteins of mitochondrial respiratory complexes Biochim. Biophys. Acta 2006, 1757, 1357-1365
9. Molberg, O.; McAdam, S.; Sollid, L. Role of tissue transglutaminase in celiac disease J. Paediatr. Gastroenterol. Nutr. 2000, 30, 232-240
10. Mangala, L.; Mehta, K. In Transglutaminases: The Family of Enzymes with Diverse Functions; Mehta, K.; Eckert, R., Eds.; Karger: Basel, 2005; pp 125-138.
11. Siegel, M.; Khosla, C. Transglutaminase 2 inhibitors and their therapeutic role in disease states Pharmacol. Ther. 2007, 115, 232-245
12. Jeitner, T.; Pinto, J.; Krasnikov, B.; Horswill, M.; Cooper, A. Transglutaminases and neurodegeneration J. Neurochem. 2009, 109, 160-166
13. Cariello, L.; de Cristofaro, T.; Zanetti, L.; Cuomo, T.; Di Maio, L.; Campanella, G.; Rinaldi, S.; Zanetti, P.; Di Lauro, R.; Varrone, S. Transglutaminase activity is related to CAG repeat length in patients with Huntington's disease Hum. Genet. 1996, 98, 633-635
14. Mastroberardino, P. G.; Iannicola, C.; Nardacci, R.; Bernassola, F.; DeLaurenzi, V.; Melino, G.; Moreno, S.; Pavone, F.; Oliverio, S.; Fesus, L.; Piacentini, M. Tissue transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease Cell Death Differ. 2002, 9, 873-880
15. Bailey, C.; Johnson, G. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms J. Neurochem. 2005, 92, 83-92
16. Chun, W.; Lesort, M.; Tucholski, J.; Faber, P. W.; MacDonald, M. E.; Ross, C. A.; Johnson, G. V. W. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells Neurobiol. Dis. 2001, 8, 391-404
17. Ruan, Q.; Quintanilla, R. A.; Johnson, G. V. Type 2 transglutaminase differentially modulates striatal cell death in the presence of wild type or mutant huntingtin J. Neurochem. 2007, 102, 25-36
18. Keillor, J. W.; Chabot, N.; Roy, I.; Mulani, A.; Leogane, O.; Pardin, C. Irreversible inhibitors of tissue transglutaminase. In Advances in Enzymology: And Related Areas of Molecular Biology; Toone, E. J., Ed.; John Wiley & Sons, Inc.: Hoboken, NJ, 2011; Vol. 78, pp 415-447.
19. Prime, M. E.; Andersen, O. A.; Barker, J. J.; Brooks, M. A.; Cheng, R. K. Y.; Toogood-Johnson, I.; Courtney, S. M.; Brookfield, F. A.; Yarnold, C. J.; Marston, R. W.; Johnson, P. D.; Johnsen, S. F.; Palfrey, J. J.; Vaidya, D.; Erfan, S.; Ichihara, O.; Felicetti, B.; Palan, S.; Pedret-Dunn, A.; Schaertl, S.; Sternberger, I.; Ebneth, A.; Scheel, A.; Winkler, D.; Toledo-Sherman, L.; Beconi, M.; Macdonald, D.; Muñoz-Sanjuan, I.; Dominguez, C.; Wityak, J. Discovery and SAR of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease J. Med. Chem. 2012, 55, 1021-1046
20. Carmi, C.; Lodola, A.; Rivara, S.; Vacondio, F.; Cavazzoni, A.; Alfieri, R. R.; Ardizzoni, A.; Petronini, P. G.; Mor, M. Epidermal growth factor receptor irreversible inhibitors: Chemical exploration of the cysteine-trap portion Mini Rev. Med. Chem. 2011, 11, 1019-1030
21. MacFaul, P. A.; Morley, A. D.; Crawford, J. J. A simple in vitro assay for assessing the reactivity of nitrile containing compounds Bioorg. Med. Chem. Lett. 2009, 19, 1136-1138